Guardant360 Tissue
Tissue-based multiomic comprehensive profiling for advanced solid tumors.
- Developer
- Guardant Health
- Intended use
- Other
- Cancer scope
- Not reported
- Specimen
- FFPE tumor tissue
- Molecular modality
- DNA methylation, DNA mutation, RNA
- Current version
- Current Guardant360 Tissue
- Evidence context
- 1 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.